MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.540
+0.070
+4.76%
After Hours: 1.550 +0.01 +0.65% 18:42 12/16 EST
OPEN
1.510
PREV CLOSE
1.470
HIGH
1.560
LOW
1.440
VOLUME
2.52M
TURNOVER
--
52 WEEK HIGH
3.780
52 WEEK LOW
0.8621
MARKET CAP
346.08M
P/E (TTM)
-1.5697
1D
5D
1M
3M
1Y
5Y
1D
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Benzinga · 5h ago
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
TipRanks · 1d ago
Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights
Benzinga · 1d ago
Allogene Wins Arbitration, Retains Full Control of Cema-Cel Rights
Reuters · 1d ago
Cellectis Wins Partial Victory in Arbitration Against Servier Over License Agreement
Reuters · 1d ago
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Barchart · 1d ago
Weekly Report: what happened at ALLO last week (1208-1212)?
Weekly Report · 1d ago
Allogene Therapeutics’ ALPHA Study: A Promising Update in CAR T Cell Therapy
TipRanks · 2d ago
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.